What is a stock summary page? Click here for an overview.
Business Description
Agentix Corp
NAICS : 541713
SIC : 2834
ISIN : US30606B2097
Description
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | -18.94 | |||||
| Debt-to-Equity | -0.07 | |||||
| Debt-to-EBITDA | -0.56 | |||||
| Piotroski F-Score | 5/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.69 | |||||
| 9-Day RSI | 36.64 | |||||
| 14-Day RSI | 40.19 | |||||
| 3-1 Month Momentum % | -49.35 | |||||
| 6-1 Month Momentum % | 62.18 | |||||
| 12-1 Month Momentum % | 151.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | |||||
| Quick Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.1 | |||||
| Shareholder Yield % | -2.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -9.62 | |||||
| EV-to-EBITDA | -9.62 | |||||
| EV-to-FCF | -22.94 | |||||
| Earnings Yield (Greenblatt) % | -10.4 | |||||
| FCF Yield % | -4.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agentix Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.006 | ||
| Beta | 2.41 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 401.3 | ||
| 14-Day RSI | 40.19 | ||
| 14-Day ATR ($) | 0.003663 | ||
| 20-Day SMA ($) | 0.080918 | ||
| 12-1 Month Momentum % | 151.83 | ||
| 52-Week Range ($) | 0.021 - 0.46 | ||
| Shares Outstanding (Mil) | 40.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agentix Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agentix Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agentix Corp Frequently Asked Questions
What is Agentix Corp(AGTX)'s stock price today?
The current price of AGTX is $0.08. The 52 week high of AGTX is $0.46 and 52 week low is $0.02.
When is next earnings date of Agentix Corp(AGTX)?
The next earnings date of Agentix Corp(AGTX) is .
Does Agentix Corp(AGTX) pay dividends? If so, how much?
Agentix Corp(AGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers